Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Buxtehude – page 87

1 242 clinical trials in Buxtehude, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Buxtehude at a glance
1 242
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 242 trials in Buxtehude

Open in trial search

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enlicitide decanoate
  • Sponsor:Merck Sharp & Dohme LLC

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSKVx000000017064
  • Sponsor:GlaxoSmithKline Biologicals

Study on Long-Term Safety and Tolerability of Iptacopan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Psoriasis

Not recruiting

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Brodalumab
  • Sponsor:Leo Pharma A/S

Study of Durvalumab, Tremelimumab, and Bevacizumab for Patients with Non-Resectable Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Klinikum Der Universitat Munchen AöR

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Effectiveness and Safety of Ralinepag for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Plasma Cell Dyscrasia Treatment in Patients with Stage IIIa AL Amyloidosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anselamimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on the Effects of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis Who Cannot Tolerate Ursodeoxycholic Acid

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bezafibrate
  • Sponsor:Intercept Pharmaceuticals Inc.

Hidradenitis

Not recruiting

Study of Eltrekibart for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Eltrekibart
  • Sponsor:Eli Lilly & Co.

Cardiac failure

Not recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Buxtehude

What the registry says about research in the country

01 Inflammatory Skin Conditions

Clinical trials focusing on moderate to severe atopic dermatitis and plaque psoriasis, evaluating novel treatments including amlitelimab, eblasakimab, and ESK-001. Research aims to assess treatment efficacy and long-term safety profiles.

  • Atopic Dermatitis Studies
  • Psoriasis Research
  • Treatment Response Assessment

Multiple studies examining maintenance therapy and dose optimization in chronic skin conditions.

02 Melanoma Research

Comprehensive studies evaluating advanced melanoma treatments, including adjuvant immunotherapy trials with pembrolizumab and novel combination therapies. Research focuses on both early-stage and metastatic disease.

  • Stage III/IV Melanoma
  • Immunotherapy Combinations
  • Disease-Free Survival

Emphasis on developing more effective treatment strategies for high-risk melanoma patients.

03 Rare Dermatological Conditions

Investigating treatments for chronic urticaria, hidradenitis suppurativa, and bullous pemphigoid. Studies evaluate innovative therapies including remibrutinib and dupilumab for these challenging conditions.

  • Chronic Urticaria Management
  • Autoimmune Skin Disorders
  • Novel Therapeutic Approaches

Focus on improving treatment outcomes for patients with resistant disease forms.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.